Loading...
Market
Will Pfizer publish full Phase 3 results of Sasanlimab in a peer-reviewed journal by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Publication in a peer-reviewed medical journal
Story
Pfizer's Phase 3 Study Shows Sasanlimab with BCG Improves Event-Free Survival in High-Risk Non-Muscle Invasive Bladder Cancer
Jan 10, 2025, 11:52 AM
Pfizer has announced positive topline results from its Phase 3 study indicating that Sasanlimab, when combined with Bacillus Calmette-Guérin (BCG), improves event-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint as assessed by investigators. Pfizer also reported that the safety profile of Sasanlimab was consistent with previous findings, suggesting a favorable outcome for this treatment approach in a challenging patient population.
View original story
Similar markets
26-50% • 25%
0-25% • 25%
51-75% • 25%
76-100% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Independent Researchers • 25%
Mainstream Media • 25%
Government Agencies • 25%
Pfizer • 25%
No • 50%
Yes • 50%
Vaccine efficacy data • 25%
Adverse side effects • 25%
Trial participant demographics • 25%
Regulatory approval process • 25%
No significant impact • 25%
Legal challenges against FDA • 25%
Policy changes in vaccine approval • 25%
Increased transparency and trust • 25%
